Crizotinib and ceritinib trigger immunogenic cell death via on-target effects

Immunogenic cell death (ICD) has initially been discovered in the context of chemotherapy. High-dose crizotinib also stimulates ICD, as we described for non-small cell lung cancer lacking activating chromosomal aberrations of ALK or ROS1, the usual targets of crizotinib, indicating that crizotinib m...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrazzuolo, Adriana, Perez-Lanzon, Maria, Liu, Peng, Maiuri, M. Chiara, Kroemer, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Author’s View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547833/
https://www.ncbi.nlm.nih.gov/pubmed/34712511
http://dx.doi.org/10.1080/2162402X.2021.1973197
_version_ 1784590456567365632
author Petrazzuolo, Adriana
Perez-Lanzon, Maria
Liu, Peng
Maiuri, M. Chiara
Kroemer, Guido
author_facet Petrazzuolo, Adriana
Perez-Lanzon, Maria
Liu, Peng
Maiuri, M. Chiara
Kroemer, Guido
author_sort Petrazzuolo, Adriana
collection PubMed
description Immunogenic cell death (ICD) has initially been discovered in the context of chemotherapy. High-dose crizotinib also stimulates ICD, as we described for non-small cell lung cancer lacking activating chromosomal aberrations of ALK or ROS1, the usual targets of crizotinib, indicating that crizotinib may act through off-target effects. However, we found that low-dose of ALK inhibitors, crizotinib and ceritinib, may stimulate ICD in anaplastic large cell lymphoma, in which ALK is activated due to a chromosomal translocation, suggesting on target ICD-promoting effects.
format Online
Article
Text
id pubmed-8547833
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-85478332021-10-27 Crizotinib and ceritinib trigger immunogenic cell death via on-target effects Petrazzuolo, Adriana Perez-Lanzon, Maria Liu, Peng Maiuri, M. Chiara Kroemer, Guido Oncoimmunology Author’s View Immunogenic cell death (ICD) has initially been discovered in the context of chemotherapy. High-dose crizotinib also stimulates ICD, as we described for non-small cell lung cancer lacking activating chromosomal aberrations of ALK or ROS1, the usual targets of crizotinib, indicating that crizotinib may act through off-target effects. However, we found that low-dose of ALK inhibitors, crizotinib and ceritinib, may stimulate ICD in anaplastic large cell lymphoma, in which ALK is activated due to a chromosomal translocation, suggesting on target ICD-promoting effects. Taylor & Francis 2021-10-25 /pmc/articles/PMC8547833/ /pubmed/34712511 http://dx.doi.org/10.1080/2162402X.2021.1973197 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Author’s View
Petrazzuolo, Adriana
Perez-Lanzon, Maria
Liu, Peng
Maiuri, M. Chiara
Kroemer, Guido
Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
title Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
title_full Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
title_fullStr Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
title_full_unstemmed Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
title_short Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
title_sort crizotinib and ceritinib trigger immunogenic cell death via on-target effects
topic Author’s View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547833/
https://www.ncbi.nlm.nih.gov/pubmed/34712511
http://dx.doi.org/10.1080/2162402X.2021.1973197
work_keys_str_mv AT petrazzuoloadriana crizotinibandceritinibtriggerimmunogeniccelldeathviaontargeteffects
AT perezlanzonmaria crizotinibandceritinibtriggerimmunogeniccelldeathviaontargeteffects
AT liupeng crizotinibandceritinibtriggerimmunogeniccelldeathviaontargeteffects
AT maiurimchiara crizotinibandceritinibtriggerimmunogeniccelldeathviaontargeteffects
AT kroemerguido crizotinibandceritinibtriggerimmunogeniccelldeathviaontargeteffects

Ejemplares similares